Company: PCRX
Filing Date: 2025-02-27
Form Type: 10-K
Source: 0001396814-25-000041
Chunk: 20

Company: Pacira BioSciences, Inc.
Filing Date: 2025-02-27
Form: 10-K
Item: Item 16
Chunk 20
---
bt extinguishment costs— (5,750)— Payment of debt issuance and financing costs(9,350)(1,163)(1,175)Net cash provided by (used in) financing activities17,363 (183,031)(401,528)Net increase (decrease) in cash and cash equivalents123,476 49,159 (481,439)Cash and cash equivalents, beginning of year153,298 104,139 585,578 Cash and cash equivalents, end of year$276,774 $153,298 $104,139 See accompanying notes to consolidated financial statements.

Pacira BioSciences, Inc.  |  2024 Annual Report on Form 10-K  |  Page F-9

PACIRA BIOSCIENCES, INC.CONSOLIDATED STATEMENTS OF CASH FLOWS (CONTINUED)(In thousands)Year Ended December 31,202420232022Supplemental cash flow information:   Cash paid for interest$15,418 $27,635 $33,295 Cash paid for income taxes, net of refunds$11,021 $4,366 $7,398 Non-cash investing and financing activities:   Issuance of common stock from conversion of 2022 convertible senior notes$— $— $3,040 Fixed assets included in accounts payable and accrued liabilities$5,565 $1,982 $5,888 Excise tax on share repurchases included in accrued liabilities$121 $— $— 

See accompanying notes to consolidated financial statements.

Pacira BioSciences, Inc.  |  2024 Annual Report on Form 10-K  |  Page F-10

Table of ContentsPACIRA BIOSCIENCES, INC.NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1—DESCRIPTION OF BUSINESS

Pacira BioSciences, Inc. and its subsidiaries (collectively, the “Company” or “Pacira”) delivers innovative, non-opioid pain therapies to transform the lives of patients. The Company’s long-acting, local analgesic, EXPAREL® (bupivacaine liposome injectable suspension), was commercially launched in the United States, or U.S., in April 2012 and approved in select European countries and the United Kingdom, or U.K., in November 2021. EXPAREL